Home Newsfeeds Citigroup Maintains Neutral on Haemonetics, Raises Price Target to $88

Citigroup Maintains Neutral on Haemonetics, Raises Price Target to $88

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the price target from $80 to $88.

byBenzinga Newsdesk

November 8, 2022

1 minute read

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the price target from $80 to $88.

Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

March 3, 2:20 PM

Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.

ADMP

B of A Securities Downgrades FedEx to Neutral, Lowers Price Target to $186

By Benzinga Newsdesk

September 16, 6:55 AM

B of A Securities analyst Ken Hoexter downgrades FedEx (NYSE:FDX) from Buy to Neutral and lowers the price target from $275 to $186.

FDX

FDA
News

Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation By FDA Of Investigational New Drug (IND) Application For NP-300, A Novel Drug Candidate For Symptomatic Relief And Treatment Of Diarrhea From Cholera And Other Pathogens

By Benzinga Newsdesk

September 29, 8:33 AM

Napo Pharmaceuticals, Inc. ("Napo"), the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the activation by the U.S. Food and

JAGX